The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The present disclosure provides means such as uses, nanoparticles, solutions, methods, kits and systems for screening target proteins for self-association properties (viscosity and opalescence) in ultra-dilute solutions. They provide means for screening a large number of target proteins at orders of magnitude lower concentrations than end-use formulations.

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Described herein are suspensions of helical polycarbodiimide polymers that cloak nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensorsboth in conjunction with carbon nanotubes, and without nanotubes.

Compositions of, methods of making, and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and at least one nonsemiconducting polymer. Compositions of, methods of making and methods of using hybrid nanoparticles comprise at least one semiconducting polymer and non-semiconducting polymers wherein the non-semiconducting polymer comprises more than one non-semiconducting polymer such that at least one non-semiconducting polymer is functionalized for bioconjugation. The hybrid nanoparticles are polarization-sensitive and have low mass ratios with large fluorescence.

The present invention relates to a zwitterionic nanoparticle, the zwitterionic nanoparticle comprising at least one nanoparticle and a zwitterionic case enclosing the nanoparticle.

Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

The present invention relates to a zwitterionic nanoparticle, the zwitterionic nanoparticle comprising at least one nanoparticle and a zwitterionic case enclosing the nanoparticle.

Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics.

The present invention provides a method for preparing catalytic particles and using them for increased sensitivity in lateral flow immunoassays. Palladium salt is reduced in the presence of a protein using sodium borohydride as a reducing agent to form brown or gray particles. These particles catalytically develop a dye to detect the presence of an analyte.